After witnessing an impressive run in 2021, Astra’s share has come under pressure in recent months. While this was partly driven by market-wide correction due to the fast-spreading Omicron variant and profitability concerns after the Q3 results, the firm remains on course to invest in promising areas. Hence, sector-leading sales growth and material medium-term earnings growth remain an unchanged scenario. As a result, our positive stock recommendation is reinforced.
22 Dec 2021
Remains attractive, despite recent profitability concerns
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Remains attractive, despite recent profitability concerns
AstraZeneca PLC (AZN:LON) | 10,689 -6841 (-0.6%) | Mkt Cap: 165,702m
- Published:
22 Dec 2021 -
Author:
Amandeep Goyal -
Pages:
3
After witnessing an impressive run in 2021, Astra’s share has come under pressure in recent months. While this was partly driven by market-wide correction due to the fast-spreading Omicron variant and profitability concerns after the Q3 results, the firm remains on course to invest in promising areas. Hence, sector-leading sales growth and material medium-term earnings growth remain an unchanged scenario. As a result, our positive stock recommendation is reinforced.